History From its pioneering beginnings as one of the first clinical research organizations (CROs) more than two decades ago to its place as one of the top three public global service providers today, PAREXEL has evolved to provide a broad range of services to the bio/pharmaceutical industry. Clients have relied on the Company to provide integrated clinical development, regulatory affairs consulting, and commercialization services, as well as to offer technologies that expedite time-to-market.

PAREXEL was founded in 1982 by Josef von Rickenbach and organic chemist Anne Sayigh to provide regulatory consulting services.  The company takes its name from Paracelsus, the Swiss physician, scientist and natural philosopher, who is celebrated as the father of modern empirical chemistry.

Over the last 25 years, PAREXEL has expanded its portfolio of services and global footprint through a combination of organic growth, alliances, and acquisitions, including the purchase of CROs in emerging geographies, in order to provide expanded capabilities for its clients’ clinical development programs.  PAREXEL now operates in 55 locations throughout 43 countries and has more than 6,300 employees. 

PAREXEL has made several innovative contributions to the advancement of the bio/pharmaceutical industry during its history, and was one of the first companies to formally define the contract service provider sector. PAREXEL broke new ground in the early 1980s by conceiving of a highly complex, multi-disciplinary and systems-oriented approach to outsourced clinical development, bringing efficiencies, speed, scalability and standardization to the process. As the industry adopted new software and Internet-based systems, PAREXEL created an industry-leading advanced technology offering. Today, PAREXEL is a front runner in providing eClinical solutions through its subsidiary Perceptive Informatics, Inc.

PAREXEL has remained focused on its mission to help clients find new ways to prevent and cure disease, contributing to the development and launch of many new drugs and treatments. PAREXEL’s experts, who have experience across a broad range of therapeutic areas, have supported nearly all of the top 50 best-selling drugs that are on the market today.